会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 52. 发明授权
    • Zoom lens system for microscope and microscope using the same
    • 变焦镜头系统用于显微镜和显微镜使用
    • US07362511B2
    • 2008-04-22
    • US10860583
    • 2004-06-04
    • Fumio Suzuki
    • Fumio Suzuki
    • G02B15/14
    • G02B15/173G02B5/04G02B21/025
    • A zoom lens system for a microscope includes, in the following order from the object side, a first lens group having a positive refractive power, a second lens group having a negative refractive power, a third lens group having a positive refractive power, and a fourth lens group having a positive refractive power. Magnification of the zoom lens system is varied by moving the second lens group and the third lens group. The zoom lens system has an entrance pupil on the object side of the first lens group, and the following conditions are satisfied: −1.3
    • 用于显微镜的变焦透镜系统按照从物体侧起的顺序包括具有正折光力的第一透镜组,具有负折光力的第二透镜组,具有正折光力的第三透镜组,以及 具有正屈光力的第四透镜组。 通过移动第二透镜组和第三透镜组来改变变焦透镜系统的放大率。 变焦透镜系统在第一透镜组的物体侧具有入射光瞳,并满足以下条件:<?in-line-formula description =“In-line formula”end =“lead”?> - 1.3 < beta2H <-0.7 <?in-line-formula description =“In-line Formulas”end =“tail”?> <?in-line-formula description =“In-line formula”end =“lead”?> - 0.1 <1 /β3L<0 <?在线公式描述=“在线公式”end =“tail”?>其中β2H是处于最高放大状态的第二透镜组的放大倍数,β3L是 第三透镜组处于最低放大状态。
    • 60. 发明授权
    • Imidazonaphthyridine derivatives
    • 咪唑并萘啶衍生物
    • US5364859A
    • 1994-11-15
    • US999658
    • 1992-12-29
    • Fumio SuzukiTakeshi KurodaShigeto KitamuraKenji Ohmori
    • Fumio SuzukiTakeshi KurodaShigeto KitamuraKenji Ohmori
    • A61K31/435A61K31/4375A61P11/08A61P29/00A61P37/08C07D471/14C07D487/04A61K31/53
    • C07D471/14
    • Disclosed are imidazonaphthyridine derivatives represented by formula (I) ##STR1## wherein: R.sup.1 represents lower alkyl or substituted or unsubstituted aryl; andX-Y-Z represents ##STR2## wherein R.sup.2 represents hydrogen, lower alkyl, alkenyl, aralkenyl, or --C (R.sup.5) H--(CH.sub.2).sub.n --R.sup.4 (wherein R.sup.4 represents substituted or unsubstituted aryl, substituted or unsubstituted pyridyl, substituted or unsubstituted furyl, hydroxy-substituted lower alkyl, lower alkanoyloxy, morpholino, lower alkanoyl, carboxy, lower alkoxycarbonyl, cycloalkyl, hydroxy, lower alkoxy, halogen or NR.sup.6 R.sup.7 wherein R.sup.6 and R.sup.7 independently represents hydrogen or lower alkyl; R.sup.5 represents hydrogen, lower alkyl, or phenyl; and n represents an integer of 0 to 3); and R.sup.3 represents hydrogen, mercapto, hydroxy, lower alkyl, or aryl and pharmaceutically acceptable sails thereof.The compounds show a potent anti-inflammatory, anti-allergic and broncho-dilative activity.
    • 公开了由式(I)表示的咪唑并吡啶衍生物其中:R1表示低级烷基或取代或未取代的芳基; 并且XYZ表示其中R2表示氢,低级烷基,烯基,芳烯基或-C(R5)H-(CH2)n-R4(其中R4表示取代或未取代的芳基,取代或未取代的吡啶基,取代或未取代的呋喃基 ,羟基取代的低级烷基,低级烷酰氧基,吗啉代,低级烷酰基,羧基,低级烷氧基羰基,环烷基,羟基,低级烷氧基,卤素或NR6R7,其中R6和R7独立地表示氢或低级烷基; R5代表氢,低级烷基或苯基 ; n表示0〜3的整数)。 并且R 3表示氢,巯基,羟基,低级烷基或芳基及其药学上可接受的风帆。 这些化合物显示有效的抗炎,抗过敏和支气管扩张活性。